Európska únia -
slovenčina -
EMA (European Medicines Agency)
humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresíva - pozrite si dokument s informáciami o produkte.
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
linoladiol n
dr. august wolff gmbh & co. kg arzneimittel, nemecko - estradiol - 46 - dermatologica
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
axhidrox
dr. august wolff gmbh & co. kg arzneimittel, nemecko - glykopyrónium - 46 - dermatologica
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
moxogamma 0,2 mg
wörwag pharma gmbh & co. kg, nemecko - moxonidín - 58 - hypotensiva
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
moxogamma 0,3 mg
wörwag pharma gmbh & co. kg, nemecko - moxonidín - 58 - hypotensiva
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
moxogamma 0,4 mg
wörwag pharma gmbh & co. kg, nemecko - moxonidín - 58 - hypotensiva
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
trederol 20 000 iu filmom obalené tablety
wörwag pharma gmbh & co. kg, nemecko - cholekalciferol - 86 - vitamina, vitagena
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
trederol 10 000 iu filmom obalené tablety
wörwag pharma gmbh & co. kg, nemecko - cholekalciferol - 86 - vitamina, vitagena
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
trederol 5 000 iu filmom obalené tablety
wörwag pharma gmbh & co. kg, nemecko - cholekalciferol - 86 - vitamina, vitagena
Európska únia -
slovenčina -
EMA (European Medicines Agency)
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukémia, lymfocytárna, chronická, b-bunka - antineoplastické činidlá - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.